spacer
home > epc > autumn 2008 > the bpo boom
PUBLICATIONS
European Pharmaceutical Contractor

The BPO Boom

There’s nothing like a darkening economic climate and rising competitive pressures to focus a business’ priorities, and few industries are being spared this experience at the moment. Like their counterparts in other commercial sectors, pharmaceutical organisations are being forced to re-examine their core and non-core activities in order to determine where new efficiencies can be found, and to drive greater productivity and competitive agility into their operations. This is leading to a surge of interest in the outsourcing of non-core activities, as pharma organisations attempt to sharpen their practices and reduce time to market.

Fortunately, as these organisations are discovering, there has been an increase in the availability and scope of managed services being offered by external specialists, which now include partial or complete outsourcing of regulatory submission operations.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Adam Sherlock is ISI’s Managing Director/Vice President Europe. During a career that spans some 20 years in the IT industry, Adam has served in senior director roles in a number of life sciences-focused organisations, including IQ Consultancy, the Synapse Partnership and medical communications agency, Gardner Caldwell. Adam was awarded his honours degree in Applied Microbiology from Liverpool University.
spacer
Adam Sherlock
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement